Fresenius Medical Care AG & Co. KGaA ADR (FMS) Quote - XNYS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Fresenius Medical Care Shares Still Attractive for Long-Term Investors

Senior Equity Analyst Julie Utterback

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA | Nov 2, 2021

Fresenius Medical Care released third-quarter results and maintained its 2021 guidance for a constant-currency profit decline in the high-teens to the mid-20s, albeit probably on the weaker end of that range given how the recent delta variant surge has affected the dialysis patient population. At first glance, this announcement and the firm's unchanged outlook through 2025 give us confidence in our fair value estimate, and we continue to view shares in this narrow moat, dialysis market leader as undervalued.

Read Full Analysis

Company Profile

Business Description

Fresenius Medical Care is the largest dialysis company in the world, treating over 345,000 patients from over 4,000 clinics across the globe as of December 2020. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Contact

Else-Kroener-Strasse 1
Bad Homburg, HE, 61352, Germany

T +49 61726090

robert.adolph(at)fmc-ag.com

www.freseniusmedicalcare.com

Sector Healthcare

Industry Medical Care Facilities

Most Recent Earnings Sep 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type —

Employees 123,528

Related

Stock Strategist Industry Reports

Healthcare Policy Changes Could Result in Opportunities

Expanded insurance rolls would be good news for the managed-care organizations and service providers we cover.

Julie Utterback

Stock Strategist

Home Dialysis to Benefit These Undervalued Providers

DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.

A Cheap, Promising Healthcare Opportunity

Both DaVita and Fresenius are well positioned among dialysis service providers, but only one of those stocks is undervalued today.

Stock Strategist

Dominance in Dialysis Digs DaVita a Moat

We think the company's advantages will protect shareholder returns over the long run.

Stock Strategist

Baxter's Headwinds Mostly Temporary

The company faces near-term challenges after the split, but we still like its moat.

Michael Waterhouse

Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price

Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.

Stock Strategist

A Shift in Health-Care M&A Activity

Recent deals have been driven more by tax strategies than therapeutic synergies.

Stock Strategist

Moats and Growth Drivers Look Solid for Post-Split Baxter

Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

Credit Insights

Treasury Bonds Take It on the Chin

Strong job growth sent Treasury rates upward, but corporate credit spreads held steady on a flood of new issues.

Stock Strategist

Strong Pipeline Helps Protect Baxter's Wide Moat From Competition

The diversified health-care firm remains remarkably profitable in tough industries.

Credit Insights

What a Difference One Economic Data Point Makes

As soon as the employment number was released Friday morning, everyone immediately became a buyer of corporate bonds.

Stock Strategist Industry Reports

Patient Trends Improving, but Reimbursement Outlook Remains Bleak for Health Service Providers

Greater accountability creates a new level of operating uncertainty.

Michael Waterhouse

Berkshire Coverage

Berkshire's 4Q Transactions Have Ted Weschler's Fingerprints All Over Them

The company made a number of significant purchases in the quarter while selling off small amounts of long-held legacy positions.

Credit Insights

All Quiet on the European Front

We are cautious that the current credit rebound will persist.

Investing Specialists

Buffett's Lieutenants Impact Berkshire's Most Recent Purchases

DIRECTV stands out among Berkshire's fourth-quarter stock purchases; IBM and Wells Fargo are other big buys.

The Morningstar Ultimate Stock-Pickers Team

Credit Insights

Markets Rally When Europe's Quiet

As investors focus on individual credit quality, they like what they see.

Stock Strategist Industry Reports

Why Dialysis Remains an Attractive Business

The dialysis industry is in a state of flux, but business models remain intact.

Premium Article

Been Waiting for a Pullback? Consider These Names

After the downturn on Thursday and Friday, these stocks are looking more attractively priced.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.